因子VIIIa模拟双特异性抗体Mim8在重型血管挑战模型中改善A型血友病小鼠出血
本研究通过筛选抗FIXa和抗FX抗体对并优化,构建双特异性抗体Mim8,模拟活化FVIII辅因子功能。Mim8在膜上高效组装并支持FX激活,表观平衡解离常数为16 nM;在A型血友病血浆和全血中,其标准化凝血酶生成和血块形成的效力分别比emicizumab序列相同类似物高13倍和18倍;在A型血友病小鼠尾静脉横断模型中观察到类似效力差异,而在严重尾夹模型中仅Mim8减少出血。
要点
- Mim8是一种活化FVIII模拟双特异性抗体,在临床前模型中显示强效止血作用。
- Mim8在A型血友病血浆和全血中标准化凝血酶生成和血块形成的效力比emicizumab类似物高13倍和18倍。
- 在严重尾夹模型中,仅Mim8减少出血,而emicizumab类似物未显示此效果。
核心结论
- Mim8是一种活化FVIII模拟物,基于临床前数据具有强效且有效的止血作用。
研究设计与样本
- 研究通过筛选抗FIXa和抗FX抗体功能对并优化功能与生物物理特性,构建双特异性抗体Mim8。
- 在A型血友病血浆、全血及A型血友病小鼠模型(尾静脉横断和严重尾夹模型)中评估Mim8的止血效果。
- 在食蟹猴中研究Mim8的药代动力学参数。
主要发现
- Mim8在膜上高效组装并与FIXa和FX结合,支持激活的表观平衡解离常数为16 nM。
- 溶液中Mim8与FIXa和FX的平衡解离常数分别为2.3 µM和1.5 µM。
- 抗FIXa臂的刺激活性使FIXa蛋白水解活性增强4个数量级。
- 在A型血友病血浆和全血中,Mim8标准化凝血酶生成和血块形成的效力分别比emicizumab序列相同类似物高13倍和18倍。
- 在A型血友病小鼠尾静脉横断模型中观察到类似效力差异;在严重尾夹模型中仅Mim8减少出血。
临床怎么用
- Mim8作为活化FVIII模拟物,临床前数据显示其具有强效止血作用,支持进一步临床开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hemophilia A is a bleeding disorder resulting from deficient factor VIII (FVIII), which normally functions as a cofactor to activated factor IX (FIXa) that facilitates activation of factor X (FX). To mimic this property in a bispecific antibody format, a screening was conducted to identify functional pairs of anti-FIXa and anti-FX antibodies, followed by optimization of functional and biophysical properties. The resulting bispecific antibody (Mim8) assembled efficiently with FIXa and FX on membranes, and supported activation with an apparent equilibrium dissociation constant of 16 nM. Binding affinity with FIXa and FX in solution was much lower, with equilibrium dissociation constant values for FIXa and FX of 2.3 and 1.5 µM, respectively. In addition, the activity of Mim8 was dependent on stimulatory activity contributed by the anti-FIXa arm, which enhanced the proteolytic activity of FIXa by 4 orders of magnitude. In hemophilia A plasma and whole blood, Mim8 normalized thrombin generation and clot formation, with potencies 13 and 18 times higher than a sequence-identical analogue of emicizumab. A similar potency difference was observed in a tail vein transection model in hemophilia A mice, whereas reduction of bleeding in a severe tail-clip model was observed only for Mim8. Furthermore, the pharmacokinetic parameters of Mim8 were investigated and a half-life of 14 days shown in cynomolgus monkeys. In conclusion, Mim8 is an activated FVIII mimetic with a potent and efficacious hemostatic effect based on preclinical data.
引用
- Østergaard H, Lund J, Greisen PJ, et al. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood. 2021. PMID: 34077951. doi:10.1182/blood.2020010331
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。